Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program [Yahoo! Finance]
Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program
Veru Inc. (NASDAQ: VERU) had its price target raised by analysts at HC Wainwright from $2.00 to $3.00. They now have a "buy" rating on the stock.
Veru to Present at the GLP-1 Based Therapeutics Summit
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024 [Yahoo! Finance]